Jula Inrig - Jan 31, 2024 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Stock symbol
TVTX
Transactions as of
Jan 31, 2024
Transactions value $
-$18,547
Form type
4
Date filed
2/2/2024, 04:05 PM
Previous filing
Jan 5, 2024
Next filing
Sep 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Award $0 +25K +70.93% $0.00 60.2K Jan 31, 2024 Direct F1
transaction TVTX Common Stock Sale -$18.5K -2.17K -3.61% $8.53 58.1K Feb 1, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Employee stock option (right to buy) Award $0 +91K $0.00 91K Jan 31, 2024 Common Stock 91K $8.93 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2 Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3 One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.